logo
Share SHARE
FONT-SIZE Plus   Neg

Zalicus To Halt Further Clinical Development With Synavive - Quick Facts

Zalicus Inc. (ZLCS) announced the results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis or RA. The company said that in the absence of a clinically meaningful benefit with Synavive compared to its active glucocorticoid component, it will discontinue further clinical development with Synavive.

The company said that Phase 2b trial demonstrated that patients treated with Synavive achieved a statistically significant improvement in signs and symptoms of moderate to severe RA compared to placebo, as measured by Disease Activity Score (DAS28-CRP), after 12 weeks of treatment, which represents a -0.9 change from baseline for Synavive (about 17% improvement) compared to a -0.5 change from baseline for placebo (about 10% improvement), but missed the key secondary endpoint of demonstrating a meaningful clinical benefit, assessed by DAS28-CRP, compared to prednisolone 2.7mg, the active glucocorticoid component in Synavive.

"Going forward we will focus our resources and efforts on advancing the clinical development of our ion channel programs including Z160, our first-in-class treatment for neuropathic pain which recently advanced into the first of two Phase 2a clinical trials, and Z944, our novel, oral, T-type calcium channel blocker which is completing multiple Phase 1 studies and if successful will advance into Phase 2 development in the first half of 2013." said Mark H.N. Corrigan, MD, CEO of Zalicus.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Jeff Bezos is now the world's second richest person. The founder and CEO of e-commerce giant Amazon.com Inc. has leapfrogged Berkshire Hathaway CEO Warren Buffett and Inditex fashion group founder Amancio Ortega to claim the second spot. In the annual letter to shareholders of hedge fund Pershing Square Capital Management L.P, CEO Bill Ackman admitted that the investment in Valeant Pharmaceuticals was a huge mistake. Valeant stock was down 19.2 percent in 2016 and tarnished the image of the hedge fund. A video posted by an outraged mother of her 13-year-old special needs son getting a thorough pat-down by a Transportation Security Administration officer at Dallas/Fort Worth International Airport has gone viral. The Texas woman, Jennifer Williamson, posted the two-minute video to Facebook on Sunday, showing her son who suffers from sensory processing disorder or SPD getting a thorough pat-down.
comments powered by Disqus
Follow RTT